Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: A Brazilian Center Experience

OBJECTIVES: Bevacizumab has been approved by the US Food and Drug Administration as a first-line therapy for metastatic non-small-cell lung cancer (NSCLC), in combination with carboplatin and paclitaxel. A single Latin American center experience was reviewed to determine the safety and efficacy of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jardim, Denis Leonardo Fontes, de Melo Gagliato, Débora, Ribeiro, Karina Braga, Shimada, Andrea Kazumi, Katz, Artur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2012
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585834/
https://www.ncbi.nlm.nih.gov/pubmed/23199211
http://dx.doi.org/10.2165/11636760-000000000-00000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585834/
https://www.ncbi.nlm.nih.gov/pubmed/23199211
http://dx.doi.org/10.2165/11636760-000000000-00000

Ejemplares similares